Evidence map›Paper›PMID 40166151›Full record

ArticlebioRxiv : the preprint server for biology2025

Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection.

Yujun Liu, Kaidong Wang, Weiguang Wang, Saarang Kashyap, Jonathan Jih, Anthony Imani, Tzung Hsiai, Z Hong Zhou

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yujun LiuCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.
Kaidong WangDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
Weiguang WangCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.
Saarang KashyapCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.
Jonathan JihCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.
Anthony ImaniCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.
Tzung HsiaiDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
Z Hong ZhouCalifornia NanoSystems Institute, University of California at Los Angeles, Los Angeles, 90095, California, USA.

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
High-Resolution CryoEM Reconstruction of Large ComplexesR01GM071940 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHOU, Z HONG · 2006 to 2025
$5.0M
In situ atomic structures of the Kaposi's sarcoma-associated herpesvirus portal-terminase complex and glycoproteinsR01DE025567 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING, ZHOU, Z HONG · 2016 to 2024
$4.0M
Shear Stress and Light-Sheets to Study Cardiac TrabeculationR01HL129727 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, MARSDEN, ALISON L · 2015 to 2024
$3.5M
Electronica Impedance to Access Metabolically Active PlaqueR01HL118650 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K · 2014 to 2022
$3.3M
Intravascular Deployment of a Wirelessly Powered Micro-PacerR01HL149808 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tzung K Hsiai · 2020 to 2026
$2.8M
Integrating Volumetric Light-Field with Computational Fluid Dynamics to Study Myocardial Trabeculation and FunctionR01HL159970 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, MARSDEN, ALISON L · 2021 to 2024
$2.0M
UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)T32HL144449 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, PAJUKANTA, PAIVI · 2020 to 2024
$1.2M
Direct Detection Device for atomic resolution cryoEM of macromolecular complexesS10OD018111 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2014 to 2014
$598k
BLRD VA I01 BX004356NHLBI NIH HHS R01 HL118650NHLBI NIH HHS R01 HL129727NHLBI NIH HHS R01 HL149808NHLBI NIH HHS R01 HL159970NHLBI NIH HHS T32 HL144449NIDCR NIH HHS R01 DE025567NIGMS NIH HHS R01 GM071940NIGMS NIH HHS R01 GM129325NIH HHS S10 OD018111
6 · The paper itself

Abstract

At the onset of the COVID-19 pandemic, the absence of a rapid and highly specific diagnostic method for the SARS-CoV-2 virus led to significant delays in detection, adversely affecting clinical outcomes. This shortfall highlights the urgent need for adaptable, scalable, and reusable diagnostic technologies to improve future pandemic responses. To address this challenge, we developed a renewable electrochemical impedance biosensor device employing a synthetic nucleotide-based therapeutic aptamer (termed 'aptasensor') targeting the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD). We demonstrate that our aptasensor can detect the Omicron BA.2 S protein within one hour and possesses concentration-dependent sensitivity at biologically relevant levels. Notably, the aptasensor is reusable after regeneration by a simple pH 2 buffer treatment. Aptamer binding to the S protein was confirmed by immunogold labeling and visualization by negative-stain electron microscopy. We used cryogenic electron microscopy (cryo-EM) to resolve high-resolution maps of the S protein in both the open and closed conformations and characterized aptamer binding to the up RBD in the open conformation. Taken together, these results establish the versatility and scalability of aptamer-based biosensors, presenting them as a potential transformative diagnostic platform for emerging pathogens. This combination of rapid detection, specificity, and renewable capabilities in a single diagnostic solution marks a significant advance in pandemic preparedness.

Indexed as

Aptamercryo-EMdetectionreceptor binding domainSARS-CoV-2specificity

Identifiers

PMID40166151
PMCPMC11957045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.